Raphael Pharmaceutical (RAPH) Accumulated Expenses (2020 - 2025)
Raphael Pharmaceutical (RAPH) posted Accumulated Expenses of $506000.0 for Q4 2025, up 6.53% sequentially from $475000.0 in Q3 2025, and up 34.93% YoY from $375000.0 in Q4 2024.
Raphael Pharmaceutical (RAPH) Accumulated Expenses (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Accumulated Expenses for 6 years, with the latest figure at $506000.0 in Q4 2025.
- Quarterly Accumulated Expenses rose 34.93% year-over-year to $506000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $506000.0 (up 34.93% YoY) and the FY2025 annual result came in at $506000.0, up 34.93% from the prior year.
- Accumulated Expenses advanced to $506000.0 in Q4 2025 per RAPH's latest filing, from $475000.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $537000.0 in Q3 2024 and troughed at $25000.0 in Q4 2023.
- A 5-year average of $294500.0 and a median of $323500.0 in 2021 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2023: Accumulated Expenses surged 2922.22% in 2021, then tumbled 88.84% in 2023.
- Over 5 years, Accumulated Expenses stood at $272000.0 in 2021, then retreated by 17.65% to $224000.0 in 2022, then sank by 88.84% to $25000.0 in 2023, then surged by 1400.0% to $375000.0 in 2024, then soared by 34.93% to $506000.0 in 2025.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $506000.0, $475000.0, and $473000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 506,000.00 |
| Sep 30, 2025 | 475,000.00 |
| Jun 30, 2025 | 473,000.00 |
| Mar 31, 2025 | 379,000.00 |
| Dec 31, 2024 | 375,000.00 |
| Sep 30, 2024 | 537,000.00 |
| Jun 30, 2024 | 392,000.00 |
| Mar 31, 2024 | 419,000.00 |
| Dec 31, 2023 | 25,000.00 |
| Sep 30, 2023 | 438,000.00 |
| Jun 30, 2023 | 141,000.00 |
| Mar 31, 2023 | 147,000.00 |
| Dec 31, 2022 | 224,000.00 |
| Sep 30, 2022 | 183,000.00 |
| Jun 30, 2022 | 64,000.00 |
| Mar 31, 2022 | 76,000.00 |
| Dec 31, 2021 | 272,000.00 |
| Sep 30, 2021 | 175,000.00 |
| Dec 31, 2020 | 9,000.00 |